During the past decade, Tjongerschans conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 3 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tjongerschans" #1 sponsor was "University Medical Center Groningen" with 3 trials, followed by "Borstkanker Onderzoek Groep" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "The Netherlands Cancer Institute" with 2 trials sponsored and "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tjongerschans" #1 collaborator was "Dutch Cancer Society" with 3 trials as a collaborator, "Roche Pharma AG" with 2 trials as a collaborator, "Agendia" with 1 trials as a collaborator, "Alcon Research" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Tjongerschans" are "Breast Cancer" (2 trials), "Cardiovascular Disease" (2 trials), "Abdominal Pain" (1 trials), "Acute Respiratory Failure" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Tjongerschans" in a lesser frequency.

Most popular intervention types in "Tjongerschans" are "Drug" (7 trials), "Other" (5 trials), "Device" (3 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "bococizumab (PF-04950615)" (2 trials), "AT1 blocker candesartan" (1 trials), "BEA 2180 BR" (1 trials) and "Best practice algorithm for postoperative care" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tjongerschans" are 14 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Tjongerschans". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Tjongerschans, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tjongerschans, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".